| MASIMO |
MASIMO |
90%
|
Masimo paid a one-time fee of $250,000. |
| ORANY |
ORANY |
72%
|
Reciprocal relationship from ORANY graph: Reciprocal relationship from NRXS graph: Reciprocal relationship from ORANY graph: Reciprocal relationship from NRXS graph: Reciprocal relationship from ORAN… |
| ORANY |
ORANY |
72%
|
alid and scientifically supported approach to the treatment of neurological conditions, and accordingly, we expect for competition in the non-implanted space to grow in the future. While many compani… |
| BOX-HILL-SURGERY-CENTER-LLC |
BOX-HILL-SURGERY-CENTER-LLC |
62%
|
the exercise of warrants and (ii) higher accounts receivable driven by IB-Stim device sales. We have incurred losses since inception and have funded our operations primarily with a combination of sal… |
| DATE-TITLE-APPLICATION-STATUS-LICENSING-STATUS-C |
DATE-TITLE-APPLICATION-STATUS-LICENSING-STATUS-C |
62%
|
ions, and academic medical society clinical practice guidelines to expand patient access to IB-Stim technology. The finalized CPT code (1/1/2026) will strengthen PENFS access as Fee Schedules and cla… |
| DELAWARE-GENERAL-CORPORATION |
DELAWARE-GENERAL-CORPORATION |
62%
|
tial monetary awards to study participants or patients; ● product recalls, withdrawals or labeling, marketing or promotional restrictions; ● loss of revenues; ● exhaustion of any available insurance … |
| INNOVATIVE-HEALTH-SOLUTIONS-INC |
INNOVATIVE-HEALTH-SOLUTIONS-INC |
62%
|
l statements are an integral part of these statements. F- 5 Neuraxis, Inc. Statements of Cash Flows 2025 2024 For the Years Ended December 31, 2025 2024 Cash Flows from Operating Activities Net loss … |
| JP-NEURAXIS-INC |
JP-NEURAXIS-INC |
62%
|
ions, and academic medical society clinical practice guidelines to expand patient access to IB-Stim technology. The finalized CPT code (1/1/2026) will strengthen PENFS access as Fee Schedules and cla… |
| MARYLAND-LLC |
MARYLAND-LLC |
62%
|
the exercise of warrants and (ii) higher accounts receivable driven by IB-Stim device sales. We have incurred losses since inception and have funded our operations primarily with a combination of sal… |
| QSR-NEURAXIS-INC |
QSR-NEURAXIS-INC |
62%
|
s review often takes significantly longer, and can take up to several years. During this review period, the FDA may request additional information or clarification of information already provided, an… |
| RITU-BHAMBHANI-LLC |
RITU-BHAMBHANI-LLC |
62%
|
the exercise of warrants and (ii) higher accounts receivable driven by IB-Stim device sales. We have incurred losses since inception and have funded our operations primarily with a combination of sal… |
| SIMCARE-ASC-LLC |
SIMCARE-ASC-LLC |
62%
|
the exercise of warrants and (ii) higher accounts receivable driven by IB-Stim device sales. We have incurred losses since inception and have funded our operations primarily with a combination of sal… |
| US-NEURAXIS-INC |
US-NEURAXIS-INC |
62%
|
ions, and academic medical society clinical practice guidelines to expand patient access to IB-Stim technology. The finalized CPT code (1/1/2026) will strengthen PENFS access as Fee Schedules and cla… |
